A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled, Multi-Dose Study of Etokimab in Patients with Eosinophilic Asthma
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Etokimab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AnaptysBio
- 08 Nov 2019 According to an AnaptysBio media release, the company has decided to postpone the initiation of its planned Phase 2b etokimab clinical trial in eosinophilic asthma, a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients, until it has the opportunity to analyze the full data set from the ATLAS trial.
- 28 Sep 2018 New trial record
- 24 Sep 2018 According to an AnaptysBio media release, the company plans to initiate this study in 2019.